REGENXBIO heads into its May 14 earnings release with short sellers slowly backing away — but by no means conceding the debate.
Short interest tells the headline story. At 13.1% of free float, the short position is substantial by any measure. It has declined steadily, however — down roughly 5% over the past week and 4% in a single session on May 11, following a month where the stock has rallied 16% to $10.24. Days to cover runs at 12 days based on official FINRA data, meaning any squeeze would take time to unwind. The borrow market is not the constraint: cost to borrow is just 0.67%, and availability remains ample, so there is no mechanical pressure pushing shorts to cover.
Options positioning has shifted modestly more cautious into the print. The put/call ratio moved to 0.58 — above its 20-day average of 0.51 and running roughly 1.4 standard deviations above the mean. That is not extreme; the 52-week high sits at 0.95, leaving considerable room before the market prices in genuine downside fear. The 11% weekly price gain has coincided with shorts trimming and call activity picking up, suggesting the recent move is being led by buyers rather than a short-squeeze dynamic.
The bull-bear debate on RGNX is a classic binary pipeline story. Bulls point to REGENXBIO's AAV vector technology, its partnerships with AbbVie and Nippon Shinyaku, and a pipeline built around rare diseases where one-time gene therapies command significant pricing power. The EPS surprise factor score ranks in the 86th percentile — the company has a strong history of beating estimates, even when those estimates reflect losses. Bears focus on regulatory risk for RGX-121, where the use of a surrogate endpoint could push commercialisation toward 2027 and drag approval probability lower. Analyst targets reflect this split: Morgan Stanley holds an Overweight rating with a $17 target while Goldman Sachs maintains Neutral at $12, and the mean target of roughly $28 reflects a cluster of more optimistic boutique names — though all of the recent analyst moves over the past few months have been downward target revisions. Note that the analyst consensus data is approximately 65 days old, so no fresh post-March activity is reflected. Peers and both gained over the past week, suggesting broader sector sentiment has lifted the tape, which may explain some of RGNX's recent recovery.
Insider activity adds a note of caution. Executives — including the CEO and CMO — have been consistent net sellers over the past several months, with the Founder and Chairman liquidating nearly $3 million of stock in late January. None of those trades are recent enough to signal a change in view ahead of this specific print, and small routine share sales carry limited signal on their own. The pattern is nonetheless worth noting in a stock where the headline short position remains elevated.
The print will test whether REGENXBIO's royalty revenues from its NAV Technology Platform — the primary revenue engine for a company still burning cash — are holding up, and whether management can offer any updated timeline clarity on RGX-121 that closes the gap between the bear and bull probability estimates.
See the live data behind this article on ORTEX.
Open RGNX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
